Third Rock Ventures
Edit

Third Rock Ventures

https://www.thirdrockventures.com
Last activity: 19.06.2025
Active
We discover, launch and build great companies based on bold ideas that meet at the intersection of science, strategy, business and medicine – where transformational science meets operational reality – providing the best opportunity to make a dramatic difference in patients’ lives.

THE THIRD ROCK TEAM
Our team has a proven record of translating disruptive technologies into valuable business enterprises. Working closely with leading scientific and business visionaries as well as industry partners, we identify opportunities to change the future of medicine and rigorously vet those ideas through our discovery process to develop the vision, strategy and plan needed to succeed.

A FORMULA FOR INNOVATION
We only invest in the best of those ideas. We are actively involved in the early stages of our companies’ development, typically serving as members of the founding management teams, to build a strong foundation, put in place the right people and culture, and set the companies on a path to scientific and operational excellence.

We believe in the companies we launch and make big initial investments, often complemented by strategic alliances, to enable our companies to advance life-changing therapies, devices and diagnostics. By creating value for patients, we create value for our investors.
Portfolio
5
Mentions
108
Location: United States, Massachusetts, Boston
Employees: 51-200
Founded date: 2007
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A

Portfolio 5

DateNameWebsiteTotal RaisedLocation
11.07.2023@Septerna_...septerna.com$290MUnited Sta...
21.12.2020Faze Medic...fazemed.com$200MUnited Sta...
24.04.2018Cedilla Th...cedillatx.com$138.8MUnited Sta...
14.02.2013Jounce The...jouncetx.com$159.3MUnited Sta...
18.10.2011Sage Thera...sagerx.com$93MUnited Sta...

Mentions in press and media 108

DateTitleDescription
19.06.2025Corvia Medical: $55 Million Raised For Treating Heart FailureCorvia Medical, a company dedicated to transforming the treatment of heart failure, announced the closing of a $55 million funding round from its existing investment syndicate, which includes Third Rock Ventures, General Catalyst Partners, ...
18.06.2025Corvia Medical Secures $55 Million to Revolutionize Heart Failure TreatmentIn a significant move for heart failure treatment, Corvia Medical, Inc. has successfully closed a $55 million funding round. This funding comes from a group of existing investors, including Third Rock Ventures, General Catalyst Partners, Ac...
17.06.2025Corvia Medical Raises $55M in FundingCorvia Medical, Inc, a Tewksbury, MA-based company dedicated to improve the treatment of heart failure, raised $55M in funding. Backers included Third Rock Ventures, General Catalyst Partners, AccelMed, Lumira Ventures, and two investors. T...
17.06.2025Corvia Medical closes $55 million funding round to complete confirmatory trial and pursue FDA approval of Corvia Atrial ShuntExisting investors provide funding to finish international RESPONDER-HF trial TEWKSBURY, Mass., June 17, 2025 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the succe...
14.05.2025BioCentury to Host Grand Rounds in Chicago: Where Translational Science Meets Investors and DealmakersJoin VCs, academic innovators and biopharma executives to connect, collaborate and accelerate innovation at the forefront of drug R&D CHICAGO–(BUSINESS WIRE)–May 14, 2025– Top decision-makers from across the biopharma ecosystem will con...
08.04.2025Merida Biosciences: $121 Million Raised For Creating Therapeutics For Multiple Autoimmune And Allergic DiseasesMerida Biosciences, a biotechnology company advancing a new class of precision therapeutics designed to selectively and durably eliminate the pathogenic antibody drivers of multiple serious autoimmune and allergic diseases, launched today w...
08.01.2025Third Rock-backed Maze Therapeutics reveals profit in US IPO filingThird Rock-backed Maze Therapeutics reveals profit in US IPO filing By ReutersJanuary 7, 202511:00 PM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link The Nasdaq logo is displayed at the Nasdaq Mark...
21.12.2024Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR StandardsCommercial validation in Europe parallels ongoing RESPONDER-HF clinical trial TEWKSBURY, Mass., Dec. 21, 2024 /PRNewswire/ -- Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure, announced today that it ...
04.12.2024Maze Therapeutics Secures $115 Million to Revolutionize Kidney Disease TreatmentMaze Therapeutics, a beacon of innovation in the biopharmaceutical landscape, has successfully raised $115 million in a Series D financing round. This funding marks a significant milestone for the South San Francisco-based company, which is...
03.12.2024Maze Therapeutics: $115 Million (Series D) Raised To Develop Precision MedicineMaze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, announced the ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In